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Ictal lack of binding to brain parenchyma
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For many decades a breakdown of the blood–brain barrier has been postulated to occur in migraine. Hypothetically this would
facilitate access of medications, such as dihydroergotamine or triptans, to the brain despite physical properties otherwise restricting
their entry. We studied the permeability of the blood–brain barrier in six migraineurs and six control subjects at rest and during acute
glyceryl trinitrate-induced migraine attacks using positron emission tomography with the novel radioligand 11C-dihydroergotamine,
which is chemically identical to pharmacologically active dihydroergotamine. The inﬂux rate constant Ki, average dynamic image and
time activity curve were assessed using arterial blood sampling and served as measures for receptor binding and thus blood–brain
barrier penetration. At rest, there was binding of 11C-dihydroergotamine in the choroid plexus, pituitary gland, and venous sinuses as
expected from the pharmacology of dihydroergotamine. However, there was no binding to the brain parenchyma, including the
hippocampus, the area with the highest density of the highest-afﬁnity dihydroergotamine receptors, and the raphe nuclei, a postulated
brainstem site of action during migraine, suggesting that dihydroergotamine is not able to cross the blood–brain barrier. This binding
pattern was identical in migraineurs during glyceryl trinitrate-induced migraine attacks as well as in matched control subjects. We
conclude that 11C-dihydroergotamine is unable to cross the blood–brain barrier interictally or ictally demonstrating that the blood–
brain barrier remains tight for dihydroergotamine during acute glyceryl trinitrate-induced migraine attacks.
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Introduction
Migraine is a disabling neurological disorder that presents
with recurrent attacks of headache (Goadsby et al., 2002),
has signiﬁcant impact on quality of life, and was recently
rated number six of the worldwide causes of disability
(Global Burden of Disease Study, 2015 #11136). The hy-
pothesis of a blood–brain barrier disruption during acute
migraine attacks has been long discussed (Harper et al.,
1977), although no human evidence supporting this is
available (Edvinsson and Tfelt-Hansen, 2008), save case
reports in severe forms of migraine with aura (Dreier
et al., 2005; Cha et al., 2007). Animal models for migraine
aura using cortical spreading depression (Gursoy-Ozdemir
et al., 2004) have postulated a mechanism of blood–brain
barrier disruption by matrix metalloproteinases, although
this too has not been conﬁrmed in humans (Ashina et al.,
2010). The question of an ictal blood–brain barrier disrup-
tion in migraine is important because whether brain treat-
ments access the brain should drive medicine development,
and certainly informs understanding of the site of action of
current therapies (Goadsby, 2013).
Here, we tested the hypothesis of blood–brain barrier
disruption during migraine attacks in humans, using PET
and the effective migraine medication dihydroergotamine
(DHE) with a priori: (i) low likelihood of interictal
blood–brain barrier penetration due to large molecular
size (Ala-Hurula et al., 1979); (ii) high sensitivity due to
a broad receptor binding proﬁle (Tfelt-Hansen et al., 2000);
and (iii) known receptor distribution in humans (Hall et al.,
1997).
Materials and methods
The study was approved by the ethics committee and the ra-
diation safety committee of the University of California, San
Francisco (10-05023 and 58605-RU-03-URH), and the US
Food and Drug Administration (IND 112,893). All subjects
gave written informed consent according to the Declaration
of Helsinki. The data have been presented in preliminary
form to the 66th Meeting of the American Academy of
Neurology (Schankin et al., 2014).
Due to the production of the radioligand solely for the study
and arterial blood sampling, exact prediction of the migraine
attack was necessary. Therefore, we decided to investigate gly-
ceryl trinitrate (GTN)-triggered migraine attacks, which have
been shown to be identical to spontaneous migraine attacks
(Iversen et al., 1989).
Experimental design
Given the excellent binding characteristics of DHE (Berde and
Schild, 1978; Goadsby and Gundlach, 1991) and our ability to
make a high speciﬁc activity ligand of not less than 11.7Ci/
nmol measured during quality control, we decided on a quali-
tative approach to detect a disruption of the blood–brain bar-
rier for DHE in each of six migraineurs and six control
subjects. Patients were healthy except for a history of migraine
with or without aura. Exclusion criteria were comorbid con-
ditions or the intake of any regular medication. Migraineurs
and control subjects were further recruited based on their his-
tory of episodic migraine and response to GTN trigger: mi-
graineurs were eligible for the PET scanning part of the study
when they developed a migraine attack following GTN
(Headache Classiﬁcation Committee of the International
Headache Society, 2013); and control subjects when they re-
mained headache-free. The GTN trigger was done as previ-
ously described and validated (Iversen, 2001): subjects
received an intravenous infusion of 0.5 mg kg1min1 GTN
over 20min, and clinical characteristics as well as vital signs
were recorded during infusion and afterwards for at least 4 h.
Of 24 migraineurs recruited, we could not trigger acute mi-
graine attacks in 13 patients, and ﬁve withdrew for personal
reasons; of 10 control subjects, two reported headache during
or after GTN-infusion, one developed signiﬁcant nausea
during the GTN infusion resulting in discontinuation of the
study, and one withdrew for personal reasons. Therefore, six
migraineurs [two male, four female, mean age  standard de-
viation (SD): 33  7 years, two with history of migraine with
aura; demographics and medical history shown in Table 1]
and six control subjects (two male, four female, 32  9
years) underwent a baseline 11C-DHE PET scan, followed by
GTN-infusion and a second 11C-DHE PET scan after 3 h
(Fig. 1). Each subject also had an interictal high-resolution
T1-weighted anatomical MRI (magnetization prepared rapid
acquisition gradient sequence) on a General Electric Signa
HDxT 3.0T scanner (GE Healthcare). During the entire
second scan, all migraineurs experienced headache fulﬁlling
the criteria for migraine without aura according to the
International Classiﬁcation of Headache Disorders, third edi-
tion-beta (ICHD-3beta, Headache Classiﬁcation Committee of
the International Headache Society, 2013) (Table 1), and all
controls remained pain-free. One patient (Patient M4) went
into a migraine attack immediately at the end of the GTN-
infusion, i.e.3 h prior to the beginning of the second scan.
Tracer synthesis
11C-DHE was synthesized in a three-step approach from
commercially available dihydroergotamine mesylate provided
by MAP Pharmaceuticals as shown in detail in the
Supplementary material and Supplementary Figs 1 and 2. In
brief: (i) N-dealkylative cyanation of DHE using cyanogen
bromide (BrCN) resulted in N-cyano-dihydroergotamine
(DHE-CN); (ii) DHE-CN was reduced to N-desmethyl-
dihydroergotamine (desmethyl-DHE) that was used as a stock
for all preparations; and (iii) Carbon-11 methylation of des-
methyl-DHE was performed with 11C methyl iodide (11CH3I)
on the FX C Pro methyl iodide synthesis unit. 11C-DHE
was puriﬁed via high-performance liquid chromatography,
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concentrated on a C18 plus sep-pak and eluted with ethanol
into saline. The ﬁnal solution was sterile ﬁltered and a sample
was analysed according to standard procedures.
Data acquisition
11C-DHE, 10–20mCi, was injected as an intravenous bolus.
Arterial blood samples were taken at the following time points:
1, 2, 3, 4, 5, 10, 15, 30, 45, and 60min. Dynamic PET scans
were acquired over 60min using a GE Discovery VCT PET/CT
scanner (GE Healthcare) in 3D mode with septa retracted. A
low-mA CT scan prior to the PET was used for attenuation
correction. Images were reconstructed by 3D iterative recon-
struction into 47 image planes (separation 3.27mm) and into a
128  128 image matrix (pixel size: 2.1  2.1 mm2).
Data analysis
Blood–brain barrier penetration of 11C-DHE was assessed
using three complementary approaches:
(i) The inﬂux rate constant Ki (1/min) was used as a measure for the
binding of 11C-DHE to the target tissue. Ki was calculated based on
the arterial input function using the Patlak graphical analysis imple-
mented in PMOD version 3.307 (PMOD Technologies, Zurich,
Switzerland). The Patlak graphical analysis is a linear model of
the two-tissue irreversible compartment model, and used to derive
Ki on each voxel. This model is appropriate for DHE due to the
very long duration of action of DHE in vitro (Mu¨ller-Schweinitzer,
1980), its low dissociation constant Kd (560pM for 5-HT1B recep-
tors), and its slow dissociation (half-life4 2h) (Hamblin et al.,
1987). The average dynamic image was used as reference for cor-
egistration with the structural MRI in SPM8 (Wellcome Department
of Imaging Neuroscience, http://www.ﬁl.ion.ucl.ac.uk/spm) simultan-
eously coregistering the MRI with the Ki image. The coregistered
MRI was segmented into grey matter and white matter using stand-
ard parameters. The spatial normalization parameters were applied
to spatially normalize the Ki image and the MRI. Areas with
Ki4 0.001/min were identiﬁed in MRIcron (http://www.mccaus
landcenter.sc.edu/mricro/mricron/index.html) with the coregistered
MRI as background and the Ki map as overlay.
Further, the maximum Ki per volume of interest was chosen as
measure for binding of 11C-DHE as it appears less observer-de-
pendent and more reproducible than the mean value (Adams
et al., 2010). The maximum Ki was obtained in MRIcron by
drawing volumes of interest on the frontal, medial temporal
(hippocampus), parietal, and occipital lobe, brainstem (raphe
nuclei), as well as thalamus. The volume of interest was spatially
normalized as described above.
(ii) The average dynamic image was calculated over the entire scan-
ning period and was compared visually between the post-GTN
scan (migraine attack in migraineurs, second scan in controls)
and the respective baseline scan.
(iii) Time activity curves were generated in PMOD using volumes of
interest over the same regions as in (i). Maximum blood–brain
barrier penetration was approximated by comparing the arterial
input of the radioligand to the measured mean standardized
uptake values (SUV) for each subject, time point (i.e. frame)
and volume of interest of the dynamic PET. The effect of mi-
graine attacks in migraineurs and GTN in controls was approxi-
mated by comparing the area under the curve using the trapezoid
approach.T
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Statistics
SPSS (v20, IBM Corp., Armonk, New York, USA) was used
for data analysis. Standard descriptive statistics were applied.
As the area under the curve of SUV was not normally distrib-
uted (assessed with Shapiro-Wilk test) the respective post-GTN
state was compared with the baseline state using the Wilcoxon
signed-rank test. When appropriate, data are presented as
mean  SD or mean  standard error of the mean (SEM).
Results
Ki maps in migraineurs and controls demonstrated binding
of 11C-DHE (Ki4 0/min) in the choroid plexus of the lat-
eral and fourth ventricles, the pituitary fossa, venous
sinuses, and facial tissue (Fig. 2A). There was no binding
(maximum Ki = 0/min) in the speciﬁc volumes of interest
within the frontal, medial temporal (hippocampus), parietal
and occipital lobes, the brainstem (raphe nuclei) or the
thalamus. The average of dynamic frames (average dynamic
image) demonstrated radioactivity in the same intracranial
areas (Fig. 2A), but none in the brain parenchyma.
Similarly, time activity curves in all volumes of interest
showed a rapid washout of the radioligand behaving like
the arterial input function. Figure 2B exemplarily illustrates
this for the hippocampus and the brainstem (raphe nuclei),
which have the highest density of 5HT1A receptors to
which DHE binds with high afﬁnity in vitro (Leysen
et al., 1996; Hall et al., 1997).
In the migraine state, there were no differences from
baseline with respect to the Ki map and average dynamic
image (Fig. 2A). The area under the time activity curve did
not differ in migraineurs between migraine state and base-
line (hippocampus: W = 7; ns/r = 6; P4 0.05; brainstem:
W = 9; ns/r = 6; P4 0.05; Wilcoxon signed-rank test) or in
controls between post-GTN state and baseline
(hippocampus: W = 7; ns/r = 6; P40.05; brainstem:
W = 4; ns/r = 6; P4 0.05; Fig. 2B).
Discussion
The parenchymal pattern of (i) no binding assessed by cal-
culating the inﬂux rate constant Ki using the gold-standard
arterial blood sampling for the input function; (ii) lack of
radioactivity in the average dynamic image; and (iii) time
activity curves behaving like the arterial input function,
indicates that 11C-DHE does not have access to receptors
in the brain parenchyma. The main metabolite of 11C-DHE
(Maurer and Frick, 1984), 11C-8’-hydroxy-DHE, is also
radioactive, and the lack of binding in PET indicates that
it does not penetrate the blood–brain barrier either.
Delayed binding of DHE or its metabolites to the brain
during the ﬁrst scan preventing binding of 11C-DHE or
its metabolites during the second scan after hypothetical
blood–brain barrier dysfunction during migraine would ex-
plain the lack of binding during migraine. This, however,
seems very unlikely due to the low injected mass of DHE
for the scans owing to the very high speciﬁc activity of our
ligand leaving most receptors unbound. The binding pat-
tern further cannot be explained by 11C-DHE being subject
to an outside transport by an active efﬂux system such as
P-glycoprotein, as the model P-glycoprotein substrate for
PET, 11C-verapamil (Wagner et al., 2009), shows substan-
tially different behaviour when compared to 11C-DHE.
Given the identical chemistry and thus pharmacology of
DHE and 11C-DHE, the broad receptor proﬁle, including
5HT1A, 5HT1B, 5HT1D receptors, -adrenoceptors and
dopamine D2 receptors (Tfelt-Hansen et al., 2000) and
the lack of binding in hippocampus and raphe nuclei,
areas with the greatest density (Hall et al., 1997) of the
high afﬁnity DHE receptors (Tfelt-Hansen et al., 2000), it
seems clear the blood–brain barrier is not altered in
Figure 1 Study design of the imaging visit. Every participant had two 11C-DHE PET scans. A baseline pain-free scan was followed by the
infusion of GTN, which served as the migraine trigger in migraineurs. The second PET scan was done 3 h after the beginning of the GTN infusion
(post-GTN). The horizontal bars illustrate the headache phase of in the migraine patients (Patients M1–6).
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Figure 2 The blood–brain barrier remains intact during migraine attacks. (A) The Ki map in the upper row shows the binding
pattern of 11C-DHE overlaid on a structural MRI. The average dynamic image is depicted in the bottom row. Except for the structures outside the
blood–brain barrier, i.e. choroid plexus, pituitary fossa, venous sinus, and facial tissue, there is no intracranial binding of 11C-DHE (Ki = 0/min).
There is only very low average radioactivity in the brain parenchyma. Due to the abundance of DHE receptors in the brain tissue, this indicates
1998 | BRAIN 2016: 139; 1994–2001 C. J. Schankin et al.
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migraine, at least not for DHE. This is supported by bind-
ing to the choroid plexus, which has 5HT1c receptors
(Brown et al., 1991) of lower afﬁnity with fenestrated capil-
laries (Strazielle and Ghersi-Egea, 2000) and probably ex-
plains the detection of DHE in the CSF (Ala-Hurula et al.,
1979). Similarly, strong binding to the pituitary gland
would be expected, given that it is outside of the blood–
brain barrier (Kuhnel, 2003) with receptors that would
bind DHE (Lawson and Gala, 1975). The absence of bind-
ing to the brain parenchyma against this background indi-
cates that there was no exchange from the vasculature to
the tissue; in other words, 11C-DHE was not able to cross
the blood–brain barrier.
An important limitation of our study is the limited spatial
resolution of PET. Due to partial volume effects, areas close
to the CSF, such as the periaqueductal grey or the area
postrema, cannot be assessed sufﬁciently (Soret et al.,
2007). Thus, the lack of binding in these areas does not
answer the question whether DHE, other ergot alkaloids or
triptans utilize central mechanisms in areas close to the
CSF, without natural blood–brain barrier penetration
(Bartsch et al., 2004), or whether they act mainly via per-
ipheral mechanisms (Saito et al., 1988). A possible central
mechanism of (other) migraine medication is for instance
reﬂected by the demonstration of the blood–brain barrier
passage by some acute migraine medication in healthy vol-
unteers (Bergstrom et al., 2006). However, it needs to be
stressed that answering the question of central mechanisms
of migraine medication has not been the purpose of our
study. A further limitation of the study is that we did not
study migraine with aura patients and cannot conclude
anything about the state of their blood–brain barrier.
Further, our study results were obtained in GTN-induced
migraine with the PET-tracer 11C-DHE, a molecule of
583.7 g/mol. This allows conclusions about blood–brain
barrier integrity only for these conditions and not for
other acute migraine medications, such as sumatriptan,
which has a smaller molecular size (295.4 g/mol). We be-
lieve that investigating the ‘per deﬁnition’ secondary head-
ache GTN-triggered migraine does not pose a signiﬁcant
bias for several reasons. First, GTN-induced migraine at-
tacks cannot be distinguished from spontaneous migraine
attacks on a clinical basis (Iversen et al., 1989) including
premonitory symptoms (Afridi et al., 2004). Second, it is
typical for migraineurs to experience attacks under certain
conditions, i.e. triggers, such as skipping meals or lack of
sleep; and thirdly, spontaneous attacks do not differ from
GTN-induced migraine on paraclinical studies including the
pattern of activation during functional brain imaging
(Afridi et al., 2005a,b). The maximum coverage of mi-
graine attack with this study is4 h in Patient M4 limiting
our ﬁndings to this period. From a clinical perspective,
however, we believe that testing the integrity of the
blood–brain barrier for this early phase of the migraine
attack is of particular importance, as early treatment
when headache is milder, i.e. therapy within 1 h after
onset of the attack, has been shown to be signiﬁcantly
more effective than late treatment (Goadsby et al., 2008).
Whether the small amounts of DHE detected in the CSF
(Ala-Hurula et al., 1979), or similarly of triptans (Goadsby,
2000; Goadsby and Sprenger, 2010) or CGRP receptor an-
tagonists (Ho et al., 2010; Hewitt et al., 2011), are sufﬁ-
cient for an effect is unclear. Only blood–brain barrier
penetrant medicines will ultimately answer that question.
Importantly, the pattern of Ki map, average dynamic
image and time activity curve did not change from baseline
during acute migraine attacks in all six migraineurs, who
had migraine attacks for the duration of the scan. It is
unlikely that the application of 11C-DHE has treated the
migraine attack successfully resulting in a closure of a
(hypothetically) broken-down blood–brain barrier as
11C-DHE was applied at tracer amounts, and patients con-
tinued to have migraine attacks over the scan period.
The identical behaviour of 11C-DHE in controls, migrain-
eurs outside and during attacks is the ﬁrst direct evidence in
human that the blood–brain barrier is not altered during
migraine without aura, at least not for DHE in GTN-trig-
gered migraines. Therefore, availability of brain sites for
certain medicines to access is not altered by migraine at-
tacks. With the limitations mentioned above this changes
our understanding of migraine pathophysiology and treat-
ment. The complex pathophysiology of migraine involves
increased trigeminovascular activity, which is likely asso-
ciated with hypothalamic and brainstem dysfunction
(Maniyar et al., 2014), such that brain access may be an
advantage, for example in preventive treatment approaches.
Figure 2 Continued
that 11C-DHE is not able to cross the blood–brain barrier at baseline state (left). Notably, there is no change of this pattern during acute migraine
attacks (right) suggesting that the blood–brain barrier remains intact during migraine headache. This was identical for all six migraineurs and
control subjects at baseline and in post-GTN state. For illustration purposes, the Ki map of one subject (Patient M6) was plotted at a threshold of
Ki4 0.001/min and was overlaid onto the subject’s coregistered MRI. The average dynamic PETwas taken from the same subject. (B) The
maximum penetration of the blood–brain barrier was further approximated for migraineurs (n = 6) and controls (n = 6) by assessing the time-
activity curves (depicting mean for all time points and mean  SEM between 10 and 60 min for the purpose of clarity) of standardized uptake
values (SUV) as exemplarily shown for hippocampus [B(i)] and brainstem [B(ii)]. In all areas, the SUV followed the arterial input radioactivity
(green crosses). This rapid washout of tracer supports the lack of parenchymal binding of 11C-DHE seen in the Ki maps in A. In all parenchymal
areas, there was no difference between the area under the curve of the post-GTN (i.e. migraine state in migraineurs) and the respective baseline
state (Wilcoxon signed-rank test: P4 0.05).
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Knowing more about the pathophysiology of migraine
makes developing new therapies possible for this most dis-
abling neurological disorder.
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